Enliven Therapeutics CMO Helen Collins sells $234,203 in stock
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics Inc., sold 5,000 shares of the company's stock on November 17, 2026. The sale occurred in two separate transactions: 4,939 shares were sold at a weighted average price of $46.8313 per share, while the remaining 61 shares were sold at a weighted average price of $47.5954.
Enliven Therapeutics shares have increased 118% over the past year, currently trading at $46.41. Despite the insider sale, analysts remain optimistic, maintaining a Strong Buy rating on the company. Ms. Collins had previously acquired 5,000 shares by exercising stock options, which were fully vested. After the sales, she now directly owns 25,000 shares of Enliven Therapeutics common stock, including restricted stock units and 96,268 derivative securities.
Recent developments include the FDA alignment for the ENABLE-2 Phase 3 study evaluating Enliven's lead asset, relcobatinib, in patients with chronic myeloid leukemia. Major investment firms such as Guggenheim, H.C. Wainwright, Morgan Stanley, and JPMorgan have shown confidence in Enliven's potential, with various price targets set between $69 and $78.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.